We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
-21.06%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$393M
AUM Growth
-$89.6M
(-19%)
Cap. Flow
+$13.6M
Cap. Flow
% of AUM
3.47%
Top 10 Holdings %
Top 10 Hldgs %
50.34%
Holding
56
New
13
Increased
11
Reduced
17
Closed
12
Top Buys
| 1 |
ADVM
Adverum Biotechnologies
ADVM
|
+$16.3M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$14.2M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
+$13.4M |
| 4 |
Invesco CurrencyShares British Pound Sterling Trust
FXB
|
+$12.6M |
| 5 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$10.6M |
Top Sells
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$20M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$15.8M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$10.9M |
| 4 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$9.02M |
| 5 |
Ascendis Pharma A/S
ASND
|
+$8.37M |
Sector Composition
| 1 | Healthcare | 63.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $30.6M | 7.79% |
401,000
-99,000
| -20% | -$8.23M |
|
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
| $29.7M | 7.56% |
+100,000
| New | +$29.5M |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $23.9M | 6.08% |
325,000
-50,000
| -13% | -$4.32M |
|
|
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $21.4M | 5.46% |
275,000
-60,000
| -18% | -$5.63M |
|
5
Sarepta Therapeutics
SRPT
$1.82B
| $16.6M | 4.22% |
220,000
-70,000
| -24% | -$8.27M |
|
|
IMMU
6
CALL
DELISTED
Immunomedics Inc
IMMU
| $15.9M | 4.06% |
1,201,000
+401,000
| +50% | +$5.89M |
|
|
SAGE
7
DELISTED
Sage Therapeutics
SAGE
| $15.4M | 3.93% |
110,000
+80,000
| +267% | +$13.4M |
|
|
8
PUT
Sarepta Therapeutics
SRPT
$1.82B
| $15.1M | 3.84% |
+200,000
| New | +$23.6M |
|
|
BHVN
9
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $14.6M | 3.72% |
350,000
+250,000
| +250% | +$10.6M |
|
|
10
Ascendis Pharma A/S
ASND
$17.1B
| $14.4M | 3.68% |
150,000
-75,000
| -33% | -$8.37M |
|
11
PUT
Invesco QQQ Trust
QQQ
$466B
| $14.2M | 3.61% |
75,000
-125,000
| -63% | -$23.7M |
|
|
FOLD
12
DELISTED
Amicus Therapeutics
FOLD
| $13.7M | 3.48% |
1,705,000
+255,000
| +18% | +$2.77M |
|
13
Axsome Therapeutics
AXSM
$11.8B
| $13.7M | 3.48% |
675,000
-175,000
| -21% | -$4.5M |
|
|
14
Invesco CurrencyShares British Pound Sterling Trust
FXB
$77.6M
| $12.6M | 3.21% |
+105,600
| New | +$12.6M |
|
|
15
BioMarin Pharmaceuticals
BMRN
$11.5B
| $12.5M | 3.18% |
+185,000
| New | +$14.2M |
|
|
IMMU
16
DELISTED
Immunomedics Inc
IMMU
| $9.61M | 2.45% |
725,000
+125,000
| +21% | +$1.84M |
|
17
Pacira BioSciences
PCRX
$1.01B
| $9.52M | 2.42% |
+250,000
| New | +$9.98M |
|
18
Iovance Biotherapeutics
IOVA
$2.23B
| $9.1M | 2.32% |
500,000
+350,000
| +233% | +$7.74M |
|
|
ADVM
19
DELISTED
Adverum Biotechnologies
ADVM
| $7.9M | 2.01% |
+145,000
| New | +$16.3M |
|
20
Rocket Pharmaceuticals
RCKT
$376M
| $7.28M | 1.86% |
625,000
+165,000
| +36% | +$2.05M |
|
|
ATNX
21
DELISTED
Athenex, Inc. Common Stock
ATNX
| $6.36M | 1.62% |
+26,125
| New | +$8.54M |
|
22
argenx
ARGX
$53.8B
| $5.7M | 1.45% |
50,000
-50,000
| -50% | -$6.76M |
|
23
Fate Therapeutics
FATE
$324M
| $5.44M | 1.39% |
+350,000
| New | +$6.71M |
|
|
TPTX
24
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $4.7M | 1.2% |
+125,000
| New | +$5.44M |
|
|
MNTA
25
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $4.54M | 1.16% |
350,000
-150,000
| -30% | -$1.81M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q3 2019 Portfolio in Review
As of Q3 2019, Ghost Tree Capital held 56 positions worth $393M, down 19% from $482M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Ghost Tree Capital deployed $13.6M of net new capital in Q3 2019, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Adverum Biotechnologies: 145,000 shares worth $7.9M.
By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 73% a quarter earlier.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $8.37M trimmed.
- Ghost Tree Capital's largest Q3 2019 buy was Adverum Biotechnologies: 145,000 shares worth $7.9M.
- Ghost Tree Capital added most to Sage Therapeutics in Q3 2019, an estimated $13.4M increase.
- Ghost Tree Capital's biggest Q3 2019 reduction was Ascendis Pharma A/S, cutting an estimated $8.37M.
- Ghost Tree Capital fully exited Acadia Pharmaceuticals in Q3 2019, selling an estimated $20M.
- Ghost Tree Capital's ten largest holdings make up 50% of its $393M portfolio in Q3 2019.
- Ghost Tree Capital opened 13 new positions and closed 12 in Q3 2019.
- Ghost Tree Capital's portfolio value fell 19% quarter-over-quarter to $393M.
Based on Ghost Tree Capital's 13F filing for Q3 2019, filed 14 Nov 2019.